These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11604049)

  • 1. Theoretical basis for the activity of thalidomide.
    Meierhofer C; Dunzendorfer S; Wiedermann CJ
    BioDrugs; 2001; 15(10):681-703. PubMed ID: 11604049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide: current and potential clinical applications.
    Calabrese L; Fleischer AB
    Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide: a review of approved and investigational uses.
    Matthews SJ; McCoy C
    Clin Ther; 2003 Feb; 25(2):342-95. PubMed ID: 12749503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential novel uses of thalidomide: focus on palliative care.
    Peuckmann V; Fisch M; Bruera E
    Drugs; 2000 Aug; 60(2):273-92. PubMed ID: 10983733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide: rationale for renewed use in immunological disorders.
    Schuler U; Ehninger G
    Drug Saf; 1995 Jun; 12(6):364-9. PubMed ID: 8527011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of thalidomide: evolving indications.
    Joglekar S; Levin M
    Drugs Today (Barc); 2004 Mar; 40(3):197-204. PubMed ID: 15148528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity.
    Kumar N; Sharma U; Singh C; Singh B
    Curr Top Med Chem; 2012; 12(13):1436-55. PubMed ID: 22650376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide: a re-look.
    Grover JK; Vats V; Gopalakrishna R; Ramam M
    Natl Med J India; 2000; 13(3):132-41. PubMed ID: 11558112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro.
    Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN
    Biomed Pharmacother; 2002 Feb; 56(1):13-9. PubMed ID: 11905505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The revival of thalidomide: an old drug with new indications].
    Laffitte E
    Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of thalidomide's history and current dermatological applications.
    Perri AJ; Hsu S
    Dermatol Online J; 2003 Aug; 9(3):5. PubMed ID: 12952752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug].
    Borges Lde G; Frõehlich PE
    Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biological response modifiers derived from thalidomide.
    Hashimoto Y
    Curr Med Chem; 1998 Jun; 5(3):163-78. PubMed ID: 9562600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.
    Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL
    J Am Acad Dermatol; 1996 Dec; 35(6):969-79. PubMed ID: 8959957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY; Achirafi A; Flageul B
    Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of thalidomide in the management of erythema nodosum leprosum.
    Walker SL; Waters MF; Lockwood DN
    Lepr Rev; 2007 Sep; 78(3):197-215. PubMed ID: 18035771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
    Amare GG; Meharie BG; Belayneh YM
    J Oncol Pharm Pract; 2021 Apr; 27(3):673-678. PubMed ID: 33249990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Action mechanism of thalidomide in treatment of multiple myeloma].
    Tsukagoshi S
    Nihon Rinsho; 2007 Dec; 65(12):2291-5. PubMed ID: 18069275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thalidomide once more in the spotlight].
    de Jong-van den Berg LT; Rutgers J; Cornel MC
    Ned Tijdschr Geneeskd; 1998 Nov; 142(46):2509-12. PubMed ID: 10028338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.